Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 433.05% | Oppenheimer | $30 → $25 | Maintains | Outperform |
| 10/13/2023 | 283.8% | Wedbush | $25 → $18 | Maintains | Outperform |
| 10/12/2023 | 283.8% | HC Wainwright & Co. | $20 → $18 | Maintains | Buy |
| 08/08/2023 | 433.05% | Wedbush | $26 → $25 | Maintains | Outperform |
| 08/08/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 539.66% | Oppenheimer | → $30 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 454.37% | Wedbush | → $26 | Reiterates | → Outperform |
| 05/12/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/28/2023 | 283.8% | Evercore ISI Group | → $18 | Initiates Coverage On | → Outperform |
| 02/24/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 12/19/2022 | 326.44% | HC Wainwright & Co. | $13 → $20 | Maintains | Buy |
| 09/29/2021 | 326.44% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 433.05% | 奧本海默 | 30 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 10/13/2023 | 283.8% | Wedbush | 25 美元 → 18 美元 | 維護 | 跑贏大盤 |
| 2023 年 12 月 10 日 | 283.8% | HC Wainwright & Co. | 20 美元 → 18 美元 | 維護 | 買 |
| 08/08/2023 | 433.05% | Wedbush | 26 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 08/08/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 06/08/2023 | 539.66% | 奧本海默 | → 30 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/12/2023 | 454.37% | Wedbush | → 26 美元 | 重申 | → 跑贏大盤 |
| 05/12/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 03/28/2023 | 283.8% | Evercore ISI 集團 | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 02/24/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 326.44% | HC Wainwright & Co. | 13 美元 → 20 美元 | 維護 | 買 |
| 09/29/2021 | 326.44% | 傑富瑞集團 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Astria Therapeutics (ATXS)?
Astria Therapeutics（ATXS）的目標價格是多少？
The latest price target for Astria Therapeutics (NASDAQ: ATXS) was reported by Oppenheimer on November 15, 2023. The analyst firm set a price target for $25.00 expecting ATXS to rise to within 12 months (a possible 433.05% upside). 11 analyst firms have reported ratings in the last year.
奧本海默於2023年11月15日公佈了Astria Therapeutics（納斯達克股票代碼：ATXS）的最新目標股價。該分析公司將目標股價定爲25.00美元，預計ATXS將在12個月內升至12個月內（可能上漲433.05％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
分析師對Astria Therapeutics（ATXS）的最新評級是多少？
The latest analyst rating for Astria Therapeutics (NASDAQ: ATXS) was provided by Oppenheimer, and Astria Therapeutics maintained their outperform rating.
奧本海默對Astria Therapeutics（納斯達克股票代碼：ATXS）的最新分析師評級由奧本海默提供，Astria Therapeutics維持跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Astria Therapeutics（ATXS）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Astria Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Astria Therapeutics的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
分析師對Astria Therapeutics（ATXS）的評級是否正確？
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $30.00 to $25.00. The current price Astria Therapeutics (ATXS) is trading at is $4.69, which is out of the analyst's predicted range.
儘管評級是主觀的，而且會發生變化，但最新的Astria Therapeutics（ATXS）評級維持不變，目標股價爲30美元至25.00美元。Astria Therapeutics（ATXS）目前的交易價格爲4.69美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。